Skip to main content

Table 2 Dose reduction and treatment interruptions due to AEs

From: Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

Treatment interruption Total (n = 279), n (%) No history of heart or liver diseases (n = 215), n (%) History of heart diseases (n = 23), n (%) History of liver diseases (n = 44), n (%) p value* p value**
Dose reduction 13 (4.7) 9 (4.2) 1 (4.3) 3 (6.8) 1.000 0.435
Treatment discontinuation 8 (2.9) 2 (0.9) 2 (8.7) 5 (11.4) 0.048 0.002
  1. *Patients without history of heart or liver diseases were compared with those with history of heart diseases using Fisher’s exact test, and p values were obtained
  2. **Patients without history of heart or liver diseases were compared with those with history of liver diseases using Fisher’s exact test, and p values were obtained